



**Walter Weder**

**Kontakt**

Walter Weder

## Publikationen (19)

Furrer K, Weder W, Eboulet E, Betticher D, Pless M, Stupp R, Krueger T, Perentes J, Schmid R, Lardinois D, Furrer M, Früh M, Peters S, Curioni-Fontecedro A, Stahel R, Rothschild S, Hayoz S, Opitz I. Extended resection for potentially operable patients with stage III non-small cell lung cancer after induction treatment. *J Thorac Cardiovasc Surg* 2022; 164:1587-1602.e5.

Jungblut L, von Garnier C, Puhan M, Tomonaga Y, Kaufmann C, Azzola A, Bürgi U, Bremerich J, Brutsche M, Christe A, Ebner L, Heverhagen J, Eich C, Franzen D, Schmitt-Opitz I, Schneiter D, Spieldenner J, Horwath N, Kohler M, Weder W, Lovis A, Meuli R, Menig M, Beigelmann-Aubry C, Niemann T, Stöhr S, Vock P, Senn O, Neuner-Jehle S, Selby K, Laures S, Otto S, Frauenfelder T. The Swiss Approach - feasibility of a national low-dose CT lung cancer screening program. *Swiss Med Wkly* 2022; 152

Rothschild S, Cathomas R, Ochsenbein A, Janthur W, Waibel C, Mach N, Froesch P, Buess M, Bohanes P, Godar G, Rusterholz C, Gonzalez M, Pless M, Mark M, Peters S, Zippelius A, Eboulet E, Savic Prince S, Betticher D, Bettini A, Früh M, Jörgen M, Lardinois D, Gelpke H, Mauti L, Britschgi C, Weder W, Swiss Group for Clinical Cancer Research (SAKK). SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial. *J Clin Oncol* 2021; 39:2872-2880.

Opitz I, Greillier L, Hoda M, Klepetko W, Lacourt A, McElnay P, Maskell N, Mutti L, Pairon J, Van Schil P, van Meerbeeck J, Waller D, Weder W, Putora P, Galateau-Salle F, Fennell D, Scherpereel A, Berghmans T, Psallidas I, Glatzer M, Rigau D, Astoul P, Bölükbas S, Boyd J, Coolen J, De Bondt C, De Ruyscher D, Durieux V, Faivre-Finn C, Cardillo G. ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. *Eur J Cardiothorac Surg*. 2020; 58:1-24.

Gachechiladze M, Soltermann A, Rulle U, Weder W, Stahel R, Kolář Z, Shani I, Hajduch M, Vbrková J, Vojta P, Smičková P, Kolek V, Überall I, Skanderová D, Škarda J, Jörgen M. Prognostic value of tumor-infiltrating lymphocytes (TILs) and their association with PD-L1 expression and DNA repair protein RAD51 in patients with resected non-small cell lung carcinoma. *Lung Cancer* 2020; 147:30-38.

Scherpereel A, Greillier L, Hoda M, Klepetko W, Lacourt A, McElnay P, Maskell N, Mutti L, Pairon J, Van Schil P, van Meerbeeck J, Waller D, Weder W, Cardillo G, Galateau-Salle F, Fennell D, Opitz I, Berghmans T, Psallidas I, Glatzer M, Rigau D, Astoul P, Bölükbas S, Boyd J, Coolen J, De Bondt C, De Ruyscher D, Durieux V, Faivre-Finn C, Putora P. ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. *Eur Respir J*. 2020; 55

Riesterer O, Krayenbuehl J, Weder W, Sabrina Stark L, Zimmermann F, Nackaerts K, Zwahlen D, Mahmut Ozsahin E, Plasswilm L, Aebbersold D, Xyrafas A, Stahel R, Ciernik I, Swiss Group for Clinical Cancer Research (SAKK). Pattern of failure after adjuvant radiotherapy following extrapleural pneumonectomy of pleural mesothelioma in the SAKK 17/04 trial. *Radiother Oncol* 2019; 138:121-125.

Kresoja-Rakic J, Cerciello F, Früh M, Stahel R, Weder W, Lam W, Martinez V, Minatel B, Ronner M, Kirschner M, Szepechinski A, Felley-Bosco E. miR-625-3p and lncRNA GAS5 in Liquid Biopsies for Predicting the Outcome of Malignant Pleural Mesothelioma Patients Treated with Neo-Adjuvant Chemotherapy and Surgery. *Noncoding RNA* 2019; 5

Früh M, Guckenberger M, Rothschild S, Lardinois D, Mach N, Mark M, Gautschi O, Thierstein S, Biaggi Rudolf C, Weder W, Stahel R, Matzinger O, Betticher D, Stupp R, Xyrafas A, Peters S, Ris H, Mirimanoff R, Ochsenbein A, Schmid R, Pless M. Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01). *J Thorac Oncol* 2018

Gachechiladze M, Soltermann A, Weder W, Stahel R, Baty F, Kolář Z, Bouchal J, Langová K, Grygárková I, Kolek V, Škarda J, Jörgen M. Prognostic and predictive value of loss of nuclear RAD51 immunoreactivity in resected non-small cell lung cancer patients. *Lung Cancer* 2017; 105:31-38.

Beck-Schimmer B, Filipovic M, Schneiter D, Weder W, Vogt A, Stuber F, Risch T, Neff T, Seeberger M, Braun J, Bonvini J, Puhan M. Which Anesthesia Regimen Is Best to Reduce Morbidity and Mortality in Lung Surgery?: A Multicenter Randomized Controlled Trial. *Anesthesiology* 2016; 125:313-21.

Stahel R, Caspar C, Eckhardt K, Schmid R, Aebersold D, Gautschi O, Nagel W, Töpfer M, Krayenbuehl J, Ribi K, Ciernik L, Mordasini C, Zippelius A, Riesterer O, Xyrafas A, Opitz I, Beyeler M, Ochsenbein A, Früh M, Cathomas R, Nackaerts K, Peters S, Mamot C, Weder W. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial. *Lancet Oncol* 2015; 16:1651-8.

Pless M, Bijelovic M, Ochsenbein A, Meier U, Mamot C, Rauch D, Gautschi O, Betticher D, Mirimanoff R, Peters S, Roth A, Zippelius A, Stupp R, Ris H, Stahel R, Weder W, Thierstein S, Gerard M, Xyrafas A, Früh M, Cathomas R. Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial. *Lancet* 2015; 386:1049-56.

Collaud S, Tischler V, Atanassoff A, Wiedl T, Komminoth P, Öhlschlegel C, Weder W, Soltermann A. Lung neuroendocrine tumors: correlation of ubiquitinylation and sumoylation with nucleo-cytosolic partitioning of PTEN. *BMC cancer* 2015; 15:74.

Ribi K, Stahel R, Ris H, Stupp R, Schmid R, Betticher D, Jörgen M, Bodis S, Weder W, Schuller J, Bernhard J, Swiss Group for Clinical Cancer Research SAKK. Individual versus standard quality of life assessment in a phase II clinical trial in mesothelioma patients: feasibility and responsiveness to clinical changes. *Lung cancer (Amsterdam, Netherlands)* 2008; 61:398-404.

Schertler T, Lardinois D, Boehm T, Weder W, Wildermuth S, Alkadhi H. Lung transplantation in Kartagener syndrome and situs inversus: potential of multidetector row computed tomography and three-dimensional postprocessing. *The Journal of thoracic and cardiovascular surgery* 2007; 134:814-5.

Gautschi O, Stahel R, Betticher D, Jörgen M, Weder W, Ratschiller D, Chassé E, Marx A, Jermann M, Huegli B, Bigosch C, Ziegler A. Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2004; 22:4157-64.

Dedes K, Szucs T, Bodis S, Jörgen M, Lowy A, Russi E, Steinert H, Weder W, Stahel R. Management and costs of treating lung cancer patients in a university hospital. *Pharmacoeconomics* 2004; 22:435-44.

Betticher D, Stahel R, Weder W, Stupp R, Egli F, Furrer M, Honegger H, Wernli M, Cerny T, Spiliopoulos A, Roth A, Hsu Schmitz S, Tötsch M, Hansen E, Joss C, von Briel C, Schmid R, Pless M, Habicht J, Ris H. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2003; 21:1752-9.

## Projekte (0)

Keine Resultate gefunden.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)